Antabio is a privately-held clinical-stage biopharmaceutical company developing novel and highly differentiated antibacterial treatments for drug-resistant infections due to CDC and WHO critical priority pathogens.

The company has a particular focus on life-threatening respiratory infections, including carbapenem-resistant nosocomial pneumonia and chronic pulmonary diseases. Antabio’s lead program, MEM-ANT3310, is being developed for the treatment of hospital-acquired infections such as nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE).

The company’s portfolio also includes ANT3273, a groundbreaking (novel class, novel mode of action) inhalation treatment of Pseudomonas aeruginosa (PA) infections, particularly those affecting patients with chronic pulmonary diseases (e.g. Bronchiectasis, Cystic Fibrosis, COPD).

Antabio has built an international team with highly successful track records, including former executives/managers from Novexel, Merck, GSK and Astra Zeneca.

The company has an impressive track record in attracting non-dilutive funding, including multi-million € awards from the Wellcome Trust, CARB-X, ARPEGE and EIC Accelerator.

Antabio has built an international team of experts to understand and resolve the most urgent unmet medical needs of the antibacterial space. We are dedicated to developing a pipeline of novel antibacterial treatments to address infections caused by WHO’s priority pathogens and fill important gaps in the antibiotic armamentarium.

Marc Lemonnier – CEO, Antabio